Markers for Detection of Prostate Cancer
Open Access
Abstract
Early detection of prostate cancer is problematic, not just because of uncertainly whether a diagnosis will benefit an individual patient, but also as a result of the imprecise and invasive nature of establishing a diagnosis by biopsy. Despite its low sensitivity and specificity for identifying patients harbouring prostate cancer, serum prostate specific antigen (PSA) has become established as the most reliable and widely-used diagnostic marker for this condition. In its wake, many other markers have been described and evaluated. This review focuses on the supporting evidence for the most prominent of these for detection and also for predicting outcome in prostate cancer.Keywords
This publication has 183 references indexed in Scilit:
- Transcriptional Control of Gene Expression by MicroRNAsCell, 2010
- Methods for metabolic evaluation of prostate cancer cells using proton and 13C HR‐MAS spectroscopy and [3‐13C] pyruvate as a metabolic substrateMagnetic Resonance in Medicine, 2009
- Characterization of ETS gene aberrations in select histologic variants of prostate carcinomaLaboratory Investigation, 2009
- ETS Gene Fusions in Prostate Cancer: From Discovery to Daily Clinical PracticeEuropean Urology, 2009
- Results from a prostate cancer admixture mapping study in African-American menHuman Genetics, 2009
- Retracted: Analysis of a serum test for prostate cancer that detects a second epitope of EPCA‐2The Prostate, 2009
- Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR‐MAS spectroscopy of biopsy tissuesMagnetic Resonance in Medicine, 2008
- The Role of SPINK1 in ETS Rearrangement-Negative Prostate CancersCancer Cell, 2008
- Return to the RNAi World: Rethinking Gene Expression and Evolution (Nobel Lecture)Angewandte Chemie International Edition, 2007
- Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancerLaboratory Investigation, 2007